Search Results - "Ignatiadis, M."

ctDNA as a predictive biomarker in advanced breast cancer: Lessons from the MONALEESA studies by Agostinetto, E., Ignatiadis, M.

Get full text

Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality? by Ignatiadis, M., Dawson, S.-J.

“…Next-generation sequencing studies have provided further evidence to support the notion that cancer is a disease characterized by Darwinian evolution. Today,…”
Get full text

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis by Bareche, Y., Venet, D., Ignatiadis, M., Aftimos, P., Piccart, M., Rothe, F., Sotiriou, C.

“…Recent efforts of genome-wide gene expression profiling analyses have improved our understanding of the biological complexity and diversity of triple-negative…”
Get full text

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 by Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., Van den Eynden, G., Baehner, F.L., Penault-Llorca, F., Perez, E.A., Thompson, E.A., Symmans, W.F., Richardson, A.L., Brock, J., Criscitiello, C., Bailey, H., Ignatiadis, M., Floris, G., Sparano, J., Kos, Z., Nielsen, T., Rimm, D.L., Allison, K.H., Reis-Filho, J.S., Loibl, S., Sotiriou, C., Viale, G., Badve, S., Adams, S., Willard-Gallo, K., Loi, S.

“…Evidence is strengthening for the morphological evaluation of tumor infiltrating lymphocytes (TILs) in breast cancer. Herein, the concepts for TILs assessment…”
Get full text

Optimal treatment for aromatase inhibitor-resistant metastatic breast cancer patients: lessons from the PEARL study by Agostinetto, E., Ignatiadis, M.

Get full text

Liquid biopsy accelerates precision medicine by Amato, O., Aftimos, P., Ignatiadis, M.

Get full text

Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer by Rothé, F., Laes, J.-F., Lambrechts, D., Smeets, D., Vincent, D., Maetens, M., Fumagalli, D., Michiels, S., Drisis, S., Moerman, C., Detiffe, J.-P., Larsimont, D., Awada, A., Piccart, M., Sotiriou, C., Ignatiadis, M.

“…Molecular screening programs use next-generation sequencing (NGS) of cancer gene panels to analyze metastatic biopsies. We interrogated whether plasma could be…”
Get full text

CDK4/6 inhibitors as neoadjuvant treatment in breast cancer—what can we learn? by Brandão, M., Ignatiadis, M.

Get full text

Patient-reported outcomes and genomic signatures: tools to tailor adjuvant endocrine treatment? by Brandão, M., Coens, C., Ignatiadis, M.

Get full text

Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients by Lambertini, M., Goldrat, O., Ferreira, A.R., Dechene, J., Azim Jr, H.A., Desir, J., Delbaere, A., t’Kint de Roodenbeke, M.-D., de Azambuja, E., Ignatiadis, M., Demeestere, I.

“…Preclinical evidence suggests a possible negative impact of deleterious BRCA mutations on female fertility. However, limited and rather conflicting clinical…”
Get full text

St Gallen International Expert Consensus on the primary therapy of early breast cancer: an invaluable tool for physicians and scientists by Ignatiadis, M., Buyse, M., Sotiriou, C.

Get full text

Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials by Solinas, C, Ceppi, M, Lambertini, M, Scartozzi, M, Buisseret, L, Garaud, S, Fumagalli, D, de Azambuja, E, Salgado, R, Sotiriou, C, Willard-Gallo, K, Ignatiadis, M

“…Highlights • This is a meta-analysis of neoadjuvant randomized studies investigating TIL in HER2-positive breast cancer. • High baseline TIL are associated…”
Get full text

Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial by Ignatiadis, M., Litière, S., Rothe, F., Riethdorf, S., Proudhon, C., Fehm, T., Aalders, K., Forstbauer, H., Fasching, P.A., Brain, E., Vuylsteke, P., Guardiola, E., Lorenz, R., Pantel, K., Tryfonidis, K., Janni, W., Piccart, M., Sotiriou, C., Rack, B., Pierga, J.-Y.

“…Trastuzumab improves the outcome of women with HER2 positive breast cancer. We aimed to assess whether trastuzumab decreases the detection rate of circulating…”
Get full text

Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting by Peeters, D J E, De Laere, B, Van den Eynden, G G, Van Laere, S J, Rothé, F, Ignatiadis, M, Sieuwerts, A M, Lambrechts, D, Rutten, A, van Dam, P A, Pauwels, P, Peeters, M, Vermeulen, P B, Dirix, L Y

“…Background: Molecular characterisation of single circulating tumour cells (CTCs) holds considerable promise for predictive biomarker assessment and to explore…”
Get full text

Predictive factors for cancer-associated thrombosis in a large retrospective single-center study by Haltout, J., Awada, A., Paesmans, M., Moreau, M., Klastersky, J., Machiels, G., Ignatiadis, M., Kotecki, N.

“…Background The relationship between cancer and thrombosis has been studied for years, but reliable guidelines for thromboprophylaxis in that situation are…”
Get full text

SYNERGY: Phase I and randomized phase II trial to investigate the addition of the anti-CD73 antibody oleclumab to durvalumab, paclitaxel and carboplatin for previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) by Maurer, C., Eiger, D., Velghe, C., Aftimos, P.G., Maetens, M., Gaye, J., Paesmans, M., Ignatiadis, M., Piccart, M., Buisseret, L.

Get full text

How I treat endocrine-dependent metastatic breast cancer by Gombos, A., Goncalves, A., Curigliano, G., Bartsch, R., Kyte, J.A., Ignatiadis, M., Awada, A.

“…Estrogen receptor-positive (ER+)/HER2-negative (HER2−), the so-called luminal-type breast cancer, is the most frequent subset, accounting for around 70% of all…”
Get full text

Liquid biopsy to test new treatment strategies in breast cancer: are we there yet? by Ignatiadis, M., Piccart, M.

Get full text

The current use and attitudes towards tumor genome sequencing in breast cancer by Gingras, I., Sonnenblick, A., de Azambuja, E., Paesmans, M., Delaloge, S., Aftimos, Philippe, Piccart, M. J., Sotiriou, C., Ignatiadis, M., Azim, H. A.

“…There is increasing availability of technologies that can interrogate the genomic landscape of an individual tumor; however, their impact on daily practice…”
Get full text

Genomic grade adds prognostic value in invasive lobular carcinoma by Metzger-Filho, O., Michiels, S., Bertucci, F., Catteau, A., Salgado, R., Galant, C., Fumagalli, D., Singhal, S.K., Desmedt, C., Ignatiadis, M., Haussy, S., Finetti, P., Birnbaum, D., Saini, K.S., Berlière, M., Veys, I., de Azambuja, E., Bozovic, I., Peyro-Saint-Paul, H., Larsimont, D., Piccart, M., Sotiriou, C.

“…The prognostic value of histologic grade (HG) in invasive lobular carcinoma (ILC) remains uncertain, and most ILC tumors are graded as HG2. Genomic grade (GG)…”
Get full text